These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28493891)

  • 1. Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.
    Gilbert PB; Excler JL; Tomaras GD; Carpp LN; Haynes BF; Liao HX; Montefiori DC; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kaewkungwal J; Kijak GH; Tovanabutra S; Francis DP; Lee C; Sinangil F; Berman PW; Premsri N; Kunasol P; O'Connell RJ; Michael NL; Robb ML; Morrow R; Corey L; Kim JH
    PLoS One; 2017; 12(5):e0176428. PubMed ID: 28493891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
    Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
    PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
    Karnasuta C; Akapirat S; Madnote S; Savadsuk H; Puangkaew J; Rittiroongrad S; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Tartaglia J; Sinangil F; Francis DP; Robb ML; de Souza MS; Michael NL; Excler JL; Kim JH; O'Connell RJ; Karasavvas N
    AIDS Res Hum Retroviruses; 2017 May; 33(5):410-423. PubMed ID: 28006952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
    J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.
    Fouda GG; Cunningham CK; McFarland EJ; Borkowsky W; Muresan P; Pollara J; Song LY; Liebl BE; Whitaker K; Shen X; Vandergrift NA; Overman RG; Yates NL; Moody MA; Fry C; Kim JH; Michael NL; Robb M; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Rerks-Ngarm S; Liao HX; Haynes BF; Montefiori DC; Ferrari G; Tomaras GD; Permar SR
    J Infect Dis; 2015 Feb; 211(4):508-17. PubMed ID: 25170104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
    Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
    Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
    Easterhoff D; Moody MA; Fera D; Cheng H; Ackerman M; Wiehe K; Saunders KO; Pollara J; Vandergrift N; Parks R; Kim J; Michael NL; O'Connell RJ; Excler JL; Robb ML; Vasan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Liao HX; Ferrari G; Seaman MS; Montefiori DC; Tomaras GD; Harrison SC; Haynes BF
    PLoS Pathog; 2017 Feb; 13(2):e1006182. PubMed ID: 28235027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
    Thongcharoen P; Suriyanon V; Paris RM; Khamboonruang C; de Souza MS; Ratto-Kim S; Karnasuta C; Polonis VR; Baglyos L; Habib RE; Gurunathan S; Barnett S; Brown AE; Birx DL; McNeil JG; Kim JH;
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):48-55. PubMed ID: 17909315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
    Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
    PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses.
    Huang Y; Alam S; Andersen-Nissen E; Carpp LN; Dintwe OB; Flach BS; Grunenberg N; Laher F; De Rosa SC; Ferrari G; Innes C; Bekker LG; Kublin JG; McElrath MJ; Tomaras GD; Gray GE; Gilbert PB
    Viruses; 2024 Aug; 16(9):. PubMed ID: 39339842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.
    Karasavvas N; Karnasuta C; Savadsuk H; Madnote S; Inthawong D; Chantakulkij S; Rittiroongrad S; Nitayaphan S; Pitisuttithum P; Thongcharoen P; Siriyanon V; Andrews CA; Barnett SW; Tartaglia J; Sinangil F; Francis DP; Robb ML; Michael NL; Ngauy V; de Souza MS; Paris RM; Excler JL; Kim JH; O'Connell RJ;
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1178-86. PubMed ID: 26234467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
    Karasavvas N; Billings E; Rao M; Williams C; Zolla-Pazner S; Bailer RT; Koup RA; Madnote S; Arworn D; Shen X; Tomaras GD; Currier JR; Jiang M; Magaret C; Andrews C; Gottardo R; Gilbert P; Cardozo TJ; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Paris R; Greene K; Gao H; Gurunathan S; Tartaglia J; Sinangil F; Korber BT; Montefiori DC; Mascola JR; Robb ML; Haynes BF; Ngauy V; Michael NL; Kim JH; de Souza MS;
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1444-57. PubMed ID: 23035746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.
    Alam SM; Liao HX; Tomaras GD; Bonsignori M; Tsao CY; Hwang KK; Chen H; Lloyd KE; Bowman C; Sutherland L; Jeffries TL; Kozink DM; Stewart S; Anasti K; Jaeger FH; Parks R; Yates NL; Overman RG; Sinangil F; Berman PW; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Karasavva N; Rerks-Ngarm S; Kim JH; Michael NL; Zolla-Pazner S; Santra S; Letvin NL; Harrison SC; Haynes BF
    J Virol; 2013 Feb; 87(3):1554-68. PubMed ID: 23175357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
    Zolla-Pazner S; deCamp A; Gilbert PB; Williams C; Yates NL; Williams WT; Howington R; Fong Y; Morris DE; Soderberg KA; Irene C; Reichman C; Pinter A; Parks R; Pitisuttithum P; Kaewkungwal J; Rerks-Ngarm S; Nitayaphan S; Andrews C; O'Connell RJ; Yang ZY; Nabel GJ; Kim JH; Michael NL; Montefiori DC; Liao HX; Haynes BF; Tomaras GD
    PLoS One; 2014; 9(2):e87572. PubMed ID: 24504509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.